Neopterin is produced by macrophages after stimulation with interferon y or lipopolysaccharide. Its production is increased in many infectious, autoimmune, and malignant diseases. The aim of this study was to examine whether, on the basis ofneopterin as a marker, liver diseases could be classified according to aetiology and stage of disease. A cohort of 264 patients with chronic liver diseases (viral, metabolic, autoimmune, toxic) and 150 normal controls were studied; 136 of the patients had cirrhosis. Increased serum neopterin concentrations were found in 41% of all patients (controls 6-0 (2.2) nmol/l), with patients in the cirrhotic stage of disease showing higher neopterin values (mean (SD) 15.7 (23.6) nmol/ml) than those in the non-cirrhotic stage (9.9 (5
lipopolysaccharide. Its production is increased in many infectious, autoimmune, and malignant diseases. The aim of this study was to examine whether, on the basis ofneopterin as a marker, liver diseases could be classified according to aetiology and stage of disease. A cohort of 264 patients with chronic liver diseases (viral, metabolic, autoimmune, toxic) and 150 normal controls were studied; 136 of the patients had cirrhosis. Increased serum neopterin concentrations were found in 41% of all patients (controls 6-0 (2.2) nmol/l), with patients in the cirrhotic stage of disease showing higher neopterin values (mean (SD) 15.7 (23.6) nmol/ml) than those in the non-cirrhotic stage (9.9 (5.5)). There were no statistically significant differences in the serum neopterin concentrations that could be considered characteristic for different stages of disease classified according to the Child criteria. Such differences in concentrations of neopterin that were found in patients with liver diseases grouped according to underlying causes were only marginal. Serum neopterin concentrations were found to be significantly lower than in any other disease group only in patients with Wilson's disease. The results suggest that activated macrophages participate in the development of chronic liver disease. Measurement of serum neopterin does not offer a reliable method for differentiating between various aetiologies of chronic liver diseases and does not help to predict severity of cirrhosis.
(Gut 1995; 37: 108-112) macrophage activation.5 7 A positive correlation between immune response and increased concentrations of neopterin has been shown in vivo and in vitro.27 Several clinical studies have shown increased neopterin concentrations in serum or urine, or both, of patients with diseases known to be associated with an activation of the cellular immune system such as viral (for example, viral hepatitis8-10), and bacterial infections,1' 12 allograft rejection, 13 14 graft versus host disease,15 and autoimmune diseases. 7 16 Thus, neopterin can be regarded as reflecting the clinical activity of these diseases.7 16 Furthermore, increased neopterin concentrations were found not only in various malignant diseases5 but also in severe infectious diseases such as HIV. In all these cases, enhanced concentrations of neopterin have been shown to have prognostic significance.5 7 Chronic liver diseases of different aetiologies may all lead to cirrhosis.17 18 The pathophysiology of such chronic inflammatory processes is poorly understood. A number of studies, however, have suggested that changes in regulatory T cell function and thus abnormal regulation of the immune response are to be considered as important factors.'9 The role of the macrophage as mediator/regulator of T cell activity and the extent of its contribution in the development of fibrosis remain to be elucidated. The aim of this study was to examine whether neopterin can be used as a marker to determine differences in liver diseases according to aetiology and stage of disease, and whether neopterin concentrations could be correlated with other laboratory and clinical parameters. We therefore studied serum neopterin concentrations in 264 patients representing a broad aetiological spectrum of cirrhotic and non-cirrhotic liver diseases.
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Methods
Interferon -y, which is released from activated T cells, and lipopolysaccharide trigger human macrophages to produce and secrete neopterin. '-3 Chronic hepatitis B virus infection (HBV infection) -this patient group comprised 37 subjects seropositive for hepatitis B surface and e-antigen for at least six months. The histological diagnoses were: chronic persistent hepatitis (n=4), chronic active hepatitis (n= 13), and cirrhosis (n=20). All patients were negative for delta antibody.
Chronic hepatitis C virus infection (HCV infection) -52 patients fulfilled the diagnostic criteria of chronic hepatitis C. Patients were entered into this group if they had biopsy findings consistent with chronic hepatitis C and were repeatedly shown to be positive for antibodies to HCV. Thirty one patients had chronic active hepatitis and 21 had cirrhosis.
Primary biliary cirrhosis -the criteria for establishing the diagnosis were the presence of disease specific anti-mitochondrial antibodies of the M2 subtype (Pharmacia ELISA) together with increased serum concentrations of alkaline phosphatase and immunoglobulin M (Ig-M) or histopathological findings consistent with primary biliary cirrhosis diagnosis (n=40), or both. This group included 46 patients, 11 of whom were in the cirrhotic stage.
Autoimmune liver disease -all 15 patients of this group fulfilled the generally accepted criteria for diagnosis of autoimmune chronic active hepatitis20 namely, presence of antinuclear or antismooth muscle autoantibodies (>1:40), or both, hypergammaglobulinaemia (mainly IgG), and liver biopsy specimens exhibiting both chronic inflammatory changes and hepatocellular necrosis. All patients had been in clinical and biochemical remission for at least six months during which they received no immunosuppressive treatment before being included in the study with relapsing disease. Cirrhosis was seen in nine of 15 symptoms of cirrhosis and 23 with stable alcoholic cirrhosis. Diagnosis was established on the basis of exclusion of other liver diseases, history of alcohol consumption of at least 80 g ethanol daily for several years, and histological findings (n=21). Diagnosis of alcohol abuse was further based on psychiatric examination. All patients considered themselves as abstaining from alcohol when they attended our outpatients department. Primary hepatocellular carcinoma -diagnosis was confirmed by histological findings or fine needle aspiration cytology in nine of 17 cases. Computed tomography and extensive increases in serum ox fetoprotein concentrations established diagnosis in the rest of the patients of this group. Fifteen patients with hepatocellular carcinoma were cirrhotic, the underlying diseases being chronic hepatitis B infection (n= 1), chronic hepatitis C infection (n= 8), haemochromatosis (n= 3), alcoholic liver disease (n=4), and a-1 antitrypsin deficiency (n= 1).
Multifactorial liver disease -28 patients, of whom 22 were cirrhotic, had a combination of two or more different causes of liver disease. In 21 patients there was a combination of HCV infection with either alcoholic liver disease (n= 1 1), HBV infection (n= 4), cxl antitrypsin deficiency (n=4), autoimmune liver disease (n=1), or Wilson's disease (n= 1). In seven patients, alcoholic liver disease was combined with cxl antitrypsin deficiency (n=4), haemochromatosis (n=-), or primary biliary cirrhosis (n=2).
Study design
Viral markers -commercially available radioimmunoassays were used to detect hepatitis B surface and e antigens and antihepatitis delta antibodies (Abbott Laboratory). Antibodies to HCV were detected using a commercially available enzyme immunoassay (second generation HCV-ELISA, Abbot diagnostics). In addition, all serum samples were tested for anti-HIV antibodies (Abbott System).
Liver biopsies -biopsy specimens were graded for their degree of periportal, portal, and lobular inflammation and fibrosis, according to the scoring system proposed by Knodell et al.22
Blood collection -venous blood was collected into sterile endotoxin free vacuum blood collection tubes and allowed to clot at room temperature for 30 minutes. Until use serum was stored at -20C. Analyses were performed after the first thawing and within six months of storage.
Neopterin in serum was measured by a commercially available radioimmunoassay (Neopterin-RIAcid, Henning Berlin GmbH, Berlin, Germany), which is based on a double antibody technique using a pre-precipitated antiserum and '251-labelled neopterin as tracer. Samples were centrifuged at 700xg and protected from light to prevent degradation of neopterin. Serum values in a cohort of 150 normal controls were 6-0 (2.2) (mean (SD)).
Neopterin (Table) , neopterin tended to be higher in patients with cirrhosis, with the exception of Wilson's disease (6.2 v 3.6 nmol/l; p=0Q06). The difference was significant only in patients with otl antitrypsin deficiency (8-3 v 23-7 nmol/l, p=0.005).
In addition, cirrhotic patients were analysed according to Child classification. Neopterin concentrations were highest in Child B patients (n=32; mean (SD): 22.7 (33 8)), but were very similar in Child A (n=83; 13.6 (20.6)) and C patients (n= 18; 13-0 (9 0)). These differences were not statistically significant when tested by multivariate analysis.
Neopterin in non-cirrhotic liver disease related to aetiology The (5.4 (2. 3) nmol/l) than patients with HCV (12.3 (6.7)) and patients with hepatocellular carcinoma (15-5 (12-5) ), at the 0 05 value after Bonferroni correction. On pairwise testing, before Bonferroni, neopterin concentrations in Wilson's disease patients were also lower than in patients with primary biliary cirrhosis (p=0.007), alcoholic liver disease (p=0*01), autoimmune liver disease (p=0.Ol), otl antitrypsin deficiency (p= 0.006), multifactorial liver disease (p= 0 002), and HBV (p=0.04). The difference in mean neopterin was not significant only when compared with haemochromatosis patients. There are only a few studies on the role of neopterin as a marker in liver disease. In two previous studies, increased urinary neopterin concentrations were reported in both acute and chronic viral hepatitis.8 9 Ninety per cent of the patients in the first group and 88.6% of those in the second group had increased neopterin concentrations compared with only 6% of patients who presumably had alcoholic liver disease.8 9 It was suggested that measurement of neopterin could help differentiate between viral and alcoholic liver diseases.8 9 Based on these studies it was recently proposed that serum neopterin could be reliably used as a marker for virus free blood products.23 Our study, however, shows that there are no significant differences between the values of neopterin in patients with chronic viral hepatitis and those with alcoholic liver disease; and there are patients with chronic viral hepatitis with normal serum neopterin values. These results are in contrast with the two previous studies, in which urinary neopterin concentrations of rather small patient groups were compared. Also, with these results, we found no strong correlation (correlation coefficient r<0525) between concentrations of serum neopterin and other biochemical parameters.
Comparison of neopterin concentrations
In a smaller Japanese study26 comparing viral and alcoholic liver disease, patients with viral hepatitis had higher neopterin concentrations. There was a substantial number of patients, however, with chronic hepatitis producing normal values of neopterin and no patients with metabolic liver diseases were studied.
In conclusion, our results suggest that activated macrophages participate in chronic liver diseases progressing to cirrhosis. Furthermore, the claim that neopterin could be used as a specific marker to differentiate various aetiologies of chronic liver diseases cannot be substantiated.
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